AKBA earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -16.34. Updated 2026-07-23.
Akebia Therapeutics (AKBA) Research Hub
Akebia Therapeutics (AKBA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.9517 USD (-0.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -16.34, market cap 0.34B. This hub links to the full technical, earnings and options research available for AKBA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.9517 USD (-0.23%) |
| 52-week range | 0.814 USD – 1.46 USD |
| Trend regime | Range |
| 14-day RSI | 54.3 (Neutral) |
| Trailing P/E | -16.34 |
| Market cap | 0.34B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for AKBA
Covered Call on AKBA: how it works, illustrative setup around the real 0.9517 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AKBA: how it works, illustrative setup around the real 0.9517 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AKBA: how it works, illustrative setup around the real 0.9517 USD price, max profit/loss, breakeven and when to use it. Educational.
AKBA technical analysis: range, last 0.9517 USD, RSI 54.3, 52w range 0.814 USD–1.46 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AKBA in?
Akebia Therapeutics (AKBA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AKBA in an uptrend or downtrend?
As of 2026-09-11, AKBA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AKBA's trailing P/E ratio?
AKBA's trailing P/E is -16.34, with a market cap of 0.34B. See the earnings research page for full valuation detail.
When does AKBA next report earnings?
AKBA is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.03 USD.